- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI Software for Fetal Heart Ultrasound Assessment
Reportedly developed on over 90,000 ultrasound exams, the BrightHeart AI software identifies suspicious findings suggestive of congenital heart defects through AI-powered evaluation of fetal heart morphology.
The Food and Drug Administration (FDA) has granted 510(k) clearance for BrightHeart’s artificial intelligence (AI)-enabled software, which may bolster ultrasound detection of congenital heart defects (CHDs) that have been estimated to occur in one of every 100 newborns.
Employing AI algorithms that were developed on over 90,000 ultrasound exams, BrightHeart’s AI software provides automated video stream analysis and detailed assessment of fetal heart morphology, which detects or rules out findings suggestive of CHDs, according to BrightHeart.
Offering detailed assessment of fetal heart morphology and automated video stream analysis, the newly FDA-cleared AI software from BrightHeart may enhance ultrasound detection of congenital heart defects. (Image courtesy of BrighHeart.)
The company says the software also offers AI assessment as to the completeness of fetal heart ultrasound exams and facilitates smooth integration into existing ultrasound workflows.
“Fetal heart assessments are among the most technically demanding aspects of prenatal ultrasound,” said Cécile Dupont, the CEO of BrightHeart. “Our AI-powered solution not only assists clinicians in detecting signs of potential abnormalities earlier but also enhances their confidence in confirming normal findings, which is equally critical for the peace of mind of expectant families.”
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.
